ValiRx - Half-year Report
VAL
Tue, 27 Sep 2016, 02:50pm BST
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
Barling Way
https://www.valirx.com/
Oliver de Giorgio-Miller, Non-Executive Chairman, comments on the significant progress that ValiRx is making in its clinical trials. ValiRx is pleased with the momentum created in the first half of 2016 as they move towards exciting clinical developmental milestones and potential value inflection points as far as VAL201, 301 and 401 therapeutic compounds are concerned. The funding recently secured provides a cash runway towards reaching these.